Zura Bio Q3 net loss narrows despite higher R&D costs

Zura Bio

13/11/2025 11:39

Overview

Zura Bio Q3 net loss narrows to $20 mln, down from $22.9 mln last year

R&D expenses rise to $11.9 mln in Q3, reflecting tibulizumab trial advancement

Outlook

Zura Bio expects topline data from tibulizumab trials in H2 2026

Company anticipates cash to fund operations through 2027

Zura Bio monitoring timelines and strategies for clinical studies

Result Drivers

TIBULIZUMAB TRIALS - Advancement of Phase 2 trials for tibulizumab in HS and SSc drove increased R&D expenses

STUDY EXECUTION - Focus on disciplined study execution and patient enrollment for tibulizumab trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.21
Q3 Net Income
-$18.04 mln
Q3 Income from Operations
-$19.52 mln
Q3 Operating Expenses
$19.52 mln
Q3 Pretax Profit
-$18.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zura Bio Ltd is $13.50, about 65.7% above its November 12 closing price of $4.63

Press Release: ID:nBw5rSky9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)